在RASmut疾病模型中通过药理CDK4/6和MEK抑制引起的可分离细胞周期停止和免疫反应
Jin Wu1, Jianxin Wang1, Thomas N O'Connor1
1Department of Molecular and Cellular Biology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
Molecular cancer therapeutics
|August 16, 2024
概括
结合CDK4/6和MEK抑制剂,如palbociclib和trametinib,通过阻止细胞生长和激活免疫通路,对软组织肉瘤有很大的希望. 这一策略为RAS突变癌症提供了新的治疗途径.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症治疗方法 癌症治疗方法
背景情况:
- CDK4/6和MEK抑制剂是新兴的癌症疗法,在RAS突变癌症中特别有效.
- 一个高通量屏幕揭示了palbociclib (CDK4/6抑制剂) 和trametinib (MEK抑制剂) 在软组织肉瘤中的协同效应.
研究的目的:
- 研究CDK4/6和MEK联合抑制在软组织肉瘤中的协同效能的机制基础.
- 探索RB1状态对治疗反应的影响,并确定相关的分子途径.
主要方法:
- 使用药物查,细胞培养,CRISPR介导的基因枯竭 (RB1) 和异种移植模型.
- 进行了细胞循环分析,增殖试验和途径丰富分析.
- 使用抑制剂GSK8612.12研究了TANK结合激酶1 (TBK1) 的作用.
主要成果:
- 组合疗法在RAS突变软组织肉瘤模型中诱导了显著的G1细胞周期停止和减少扩散.
- 减少RB1减少了对CDK4/6和MEK联合抑制的反应,在体外和体内得到证实.
- 治疗激活了干扰素通路和上调的逆转录病毒元素,TBK1抑制有选择地阻断了这些干扰素相关的基因表达.
结论:
- 结合CDK4/6和MEK抑制是一种有前途的治疗策略,用于软组织肉瘤,特别是具有RAS突变的软组织肉瘤.
- RB1状态是对这种组合疗法的反应的关键决定因素.
- 该组合引发可分离的细胞周期和表观遗传反应,包括干扰素通路激活,为新的治疗组合提供了洞察力.
相关概念视频
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
DNA Damage can Stall the Cell Cycle
9.1K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.1K
Separation of Sister Chromatids
3.6K
At the transition from prophase to metaphase, there is a reduction in cohesion along the chromosomal arms, resulting in the resolution of sister chromatids. However, residual cohesin connections remain to hold the sister chromatids together until the transition from metaphase to anaphase. The residual connection prevents any premature separation of sister chromatids, blocking the risks of aneuploidy within the daughter cells.
At the onset of anaphase, separase, a proteolytic enzyme, is...
At the onset of anaphase, separase, a proteolytic enzyme, is...
3.6K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Negative Regulator Molecules
35.2K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.2K
MAPK Signaling Cascades
5.3K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.3K


